keyword
MENU ▼
Read by QxMD icon Read
search

Cardio-oncology

keyword
https://www.readbyqxmd.com/read/28631773/-cardiovascular-complications-of-cancer-chemotherapy-the-need-for-cardio-oncology
#1
Alberto Dolara
Traditional chemotherapic agents as antraciclines and radiumtherapy are known to be the cause of cardiovascular complications from many years. Nevertheless also recent drugs, which were initially considered effective only on cancer cells are now recognized to exert negative effects also on the cardiovascular system. The frequency and the entity of the effects are variable for each drug and depend from the clinical status of the patient. It is therefore necessary the creation of a team of oncologists and cardiologists for the prevention and therapy of cardiovascular complications...
June 2017: Recenti Progressi in Medicina
https://www.readbyqxmd.com/read/28606695/cardio-oncology-what-is-the-best-practice-we-can-all-strive-for
#2
EDITORIAL
Daniel Lenihan
No abstract text is available yet for this article.
August 15, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28547673/valvular-heart-disease-in-cancer-patients-etiology-diagnosis-and-management
#3
REVIEW
Merrill H Stewart, Eiman Jahangir, Nichole M Polin
Cardiac valvular disease as consequence of radiation and chemotherapy during treatment for malignancy is growing in its awareness. While the overwhelming emphasis in this population has been on the monitoring and preservation of left ventricular systolic function, we are now developing a greater appreciation for the plethora of cardiac sequelae beyond this basic model. To this end many institutions across the country have developed cardio-oncology programs, which are collaborative practices between oncologists and cardiologists in order to minimize a patient's cardiovascular risk while allowing them to receive the necessary treatment for their cancer...
July 2017: Current Treatment Options in Cardiovascular Medicine
https://www.readbyqxmd.com/read/28515362/insulin-supplementation-attenuates-cancer-induced-cardiomyopathy-and-slows-tumor-disease-progression
#4
James T Thackeray, Stefan Pietzsch, Britta Stapel, Melanie Ricke-Hoch, Chun-Wei Lee, Jens P Bankstahl, Michaela Scherr, Jörg Heineke, Gesine Scharf, Arash Haghikia, Frank M Bengel, Denise Hilfiker-Kleiner
Advanced cancer induces fundamental changes in metabolism and promotes cardiac atrophy and heart failure. We discovered systemic insulin deficiency in cachectic cancer patients. Similarly, mice with advanced B16F10 melanoma (B16F10-TM) or colon 26 carcinoma (C26-TM) displayed decreased systemic insulin associated with marked cardiac atrophy, metabolic impairment, and function. B16F10 and C26 tumors decrease systemic insulin via high glucose consumption, lowering pancreatic insulin production and producing insulin-degrading enzyme...
May 18, 2017: JCI Insight
https://www.readbyqxmd.com/read/28505345/cardio-oncology-a-multidisciplinary-approach-for-detection-prevention-and-management-of-cardiac-dysfunction-in-cancer-patients
#5
Kazuko Tajiri, Kazutaka Aonuma, Ikuo Sekine
Cardiac dysfunction that develops during or after completion of cancer therapy is a growing health concern that should be addressed in a multidisciplinary setting. Cardio-oncology is a new discipline that focuses on screening, monitoring and treating cardiovascular disease during and after cancer treatment. A baseline cardiovascular risk assessment is essential. For high-risk patients, a tailored and detailed plan for cardiovascular management throughout treatment and beyond should also be established. Anthracycline and/or trastuzumab-containing chemotherapy and chest-directed radiation therapy are well known cardiotoxic cancer therapies...
May 15, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28499724/cardio-oncology-in-the-older-adult
#6
REVIEW
Prajwal Reddy, Chetan Shenoy, Anne H Blaes
Heart disease and cancer are the leading causes of death in older adults. Many first-line cancer treatments have the potential for cardiotoxicity. Age-related risk factors, pre-existing cardiac disease, and a high prevalence of comorbidities are reasons for increased cardiotoxicity in older adults. Concerns regarding cardiotoxicity may lead to frailty bias and undertreatment, resulting in suboptimal outcomes. There is an urgent need for geriatric-specific evidence and guidelines to help tailor care for this vulnerable group...
May 9, 2017: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/28484995/management-of-cad-in-patients-with-active-cancer-the-interventional-cardiologists-perspective
#7
REVIEW
Dana Elena Giza, Kostas Marmagkiolis, Elie Mouhayar, Jean-Bernard Durand, Cezar Iliescu
PURPOSE OF REVIEW: Coronary artery disease in patients with active cancer presents particular challenges for clinicians, as optimum management is required in order to treat the underlying malignancy and to reduce morbidity and mortality associated with cardiovascular diseases. Special considerations must be made in respect to either primary or secondary thrombocytopenia, the presence of coagulopathies and the propensity of bleeding, vascular access complications, and increased risk of stent thrombosis...
June 2017: Current Cardiology Reports
https://www.readbyqxmd.com/read/28474324/role-of-imaging-in-cardio-oncology
#8
REVIEW
Erick Avelar, Caitlin R Strickland, Guido Rosito
Recent advances in cancer treatment and research have greatly improved survival rates for patients with cancer. However, many of these cancer survivors are developing cardiac disease-most commonly heart failure as a result of this treatment. Certain chemotherapeutic agents, including anthracyclines and trastuzumab, have been linked to cardiotoxicity-induced cardiomyopathy in cancer patients. It has been reported as early as during infusion and as late as several years following treatment. Radiation therapy, particularly to the left breast, has also been linked to cardiac disease...
June 2017: Current Treatment Options in Cardiovascular Medicine
https://www.readbyqxmd.com/read/28469492/diagnostic-strategies-for-early-recognition-of-cancer-therapeutics-related-cardiac-dysfunction
#9
REVIEW
Carlos R Manrique, Michael Park, Nidhish Tiwari, Juan Carlos Plana, Mario J Garcia
Cardiovascular toxicity in the form of cardiac dysfunction continues to be an obstacle for patients with cancer. Survival and quality of life of cancer survivors are frequently affected by increased incidence of cardiovascular disease. The involvement of the cardiovascular system by primary or secondary malignancies, as well as its dysfunction secondary to the administration of antineoplastics, has led to the development of a new discipline called Cardio-Oncology, an exciting cardiology subspecialty with more questions than answers and as a result an enormous opportunity for research in the field...
2017: Clinical Medicine Insights. Cardiology
https://www.readbyqxmd.com/read/28441369/cardiac-magnetic-resonance-imaging-in-oncology
#10
Daniel Jeong, Aarti Patel, Christopher J Francois, Kenneth L Gage, Michael G Fradley
BACKGROUND: Cardiac magnetic resonance imaging (MRI) is emerging as an important diagnostic modality in the management of cardiovascular-related dysfunction in oncological diseases. Advances in imaging techniques have enhanced the detection and evaluation of cardiac masses; meanwhile, innovative applications have created a growing role for cardiac MRI for the management of cardiotoxicity caused by cancer therapies. METHODS: An overview is provided of the clinical indications and technical considerations of cardiac MRI...
April 2017: Cancer Control: Journal of the Moffitt Cancer Center
https://www.readbyqxmd.com/read/28425056/ischemic-heart-disease-special-considerations-in-cardio-oncology
#11
REVIEW
Dana Elena Giza, Fernando Boccalandro, Juan Lopez-Mattei, Gloria Iliescu, Kaveh Karimzad, Peter Kim, Cezar Iliescu
The interplay and balance between the competing morbidity and mortality of cardiovascular diseases and cancer have a significant impact on both short- and long-term health outcomes of patients who survived cancer or are being treated for cancer. Ischemic heart disease in patients with cancer or caused by cancer therapy is a clinical problem of emerging importance. Prompt recognition and optimum management of ischemic heart disease mean that patients with cancer can successfully receive therapies to treat their malignancy and reduce morbidity and mortality due to cardiovascular disease...
May 2017: Current Treatment Options in Cardiovascular Medicine
https://www.readbyqxmd.com/read/28421484/the-role-of-biomarkers-in-detection-of-cardio-toxicity
#12
REVIEW
Kevin S Shah, Eric H Yang, Alan S Maisel, Gregg C Fonarow
The goal of this paper is to review the current literature on the role of biomarkers in the detection and management of patients with cardio-oncologic disease. The role of biomarker surveillance in patients with known cardiac disease, as a result of chemotherapy or with the potential to develop cardio-toxicity, will be discussed. In addition, the studies surrounding sub-clinical cardiac toxicity monitoring during therapy, identification of high-risk patients prior to therapy, and tailoring oncologic therapies to potential biomarker risk profiles are reviewed...
June 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/28410144/cardiotoxicity-in-oncology-and-coronary-microcirculation-future-challenges-in-theranostics
#13
Giovanni Peretto, Davide Lazzeroni, Carmem L Sartorio, Paolo G Camici
Many of the patients undergoing chemotherapy or radiotherapy for cancer are at increased risk of developing cardiovascular diseases. Recent evidence suggests that cardiac dysfunction and subsequent heart failure are mainly due to vascular toxicity rather than only to due to myocyte toxicity. However, not all of the vascular toxicity of cancer therapies can be explained by epicardial coronary artery disease. In fact, in the last decades, it has been found that myocardial ischemia may occur as a consequence of structural or functional dysfunction of the complex network of vessels, which cannot be seen by a coronary angiography: the coronary microcirculation...
June 1, 2017: Frontiers in Bioscience (Landmark Edition)
https://www.readbyqxmd.com/read/28401456/cardiovascular-complications-associated-with-novel-cancer-immunotherapies
#14
REVIEW
Varun Jain, Jaspreet Bahia, Mahsa Mohebtash, Ana Barac
Immune therapies represent a quantum leap in the fight against cancer. Recently approved immune checkpoint inhibitors that target receptors involved in immune escape of cancer cells (including cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein-1 (PD-1), and programmed cell death protein ligand-1 (PD-L1) are increasingly being used for therapeutic benefit in a number of cancers. The robust anti-cancer activity of these agents has been accompanied by the recognition of new adverse effects, often due to the over activation of immune system, that may limit their therapeutic benefit and adversely impact outcomes...
May 2017: Current Treatment Options in Cardiovascular Medicine
https://www.readbyqxmd.com/read/28365180/practices-in-management-of-cancer-treatment-related-cardiovascular-toxicity-a-cardio-oncology-survey
#15
Ludovic Jovenaux, Jennifer Cautela, Noemie Resseguier, Michele Pibarot, Myriam Taouqi, Morgane Orabona, Johan Pinto, Michael Peyrol, Jeremie Barraud, Marc Laine, Laurent Bonello, Franck Paganelli, Fabrice Barlesi, Franck Thuny
BACKGROUND: Cardiovascular toxicity has become a challenging issue during cancer therapy. Nonetheless, there is a lack of consensual guidelines for their management. We aimed to determine the current practices of oncologists regarding cardiovascular toxicity related to anthracyclines, trastuzumab and angiogenic inhibitors and to gather their opinions on the development of cardio-oncology programs. METHODS: A cross-sectional declarative study was submitted to French oncologists in the form of an individual, structured questionnaire...
March 21, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28336372/doxorubicin-targets-multiple-players-a-new-view-of-an-old-problem
#16
REVIEW
Donato Cappetta, Francesca Rossi, Elena Piegari, Federico Quaini, Liberato Berrino, Konrad Urbanek, Antonella De Angelis
Anthracycline cardiotoxicity remains a serious problem in paediatric and adult cancer survivors, and the advancement of cardio-oncology is a necessary step for an effective care of the patients that experience adverse cardiovascular effects. In this review, we discuss the multiple instruments used by clinicians that constitute the current strategies for primary and secondary prevention aiming at contrasting the onset of early and late doxorubicin-induced cardiotoxic events. The importance of early detection of cardiotoxicity and the following pharmacological therapy has been acknowledged with the emphasis put on impaired diastolic function, an increasingly recognized precocious sign of doxorubicin cardiotoxicity with an emerging scientific and clinical interest...
March 20, 2017: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/28330611/rationale-for-cardio-oncology-units
#17
Lara F Nhola, Hector R Villarraga
With the rapidly rising number of patients surviving cancer, often in the setting of new or pre-existing cardiovascular disease and risk factors, a need has arisen for a specialty within the realm of cardiovascular care that can evaluate and manage these patients along with our colleagues in oncology and hematology. By the same token, all health care providers involved in the care of cancer patients with heart disease must be fully aware of the impact of adverse cardiovascular effects on the survival of these patients...
March 16, 2017: Revista Española de Cardiología
https://www.readbyqxmd.com/read/28320853/cardio-oncology-vascular-endothelial-growth-factor-inhibitors-salt-and-macrophages-a-complicated-interaction
#18
Javid Moslehi, Arvind K Pandey, Nirmanmoh Bhatia
No abstract text is available yet for this article.
March 20, 2017: Hypertension
https://www.readbyqxmd.com/read/28316172/-cardio-oncology-in-the-bud-opportunities-and-challenges
#19
Y L Xia, Y Zhang
No abstract text is available yet for this article.
March 24, 2017: Zhonghua Xin Xue Guan Bing za Zhi
https://www.readbyqxmd.com/read/28315122/cardio-oncology-the-nuclear-option
#20
REVIEW
Jorge A Alvarez, Raymond R Russell
PURPOSE OF REVIEW: Cardio-oncology focuses increased effort to decrease cancer treatment-related cardiotoxicity while continuing to improve outcomes. We sought to synthesize the latest in nuclear cardiology as it pertains to the assessment of left ventricular function in preventative guidelines and comparison to other modalities, novel molecular markers of pre-clinical cardiotoxicity, and its role in cardiac amyloid diagnosis. RECENT FINDINGS: Planar ERNA (equilibrium radionuclide angiocardiography) provides a reliable and proven means of monitoring and preventing anthracycline cardiotoxicity, and SPECT ERNA using solid-state gamma cameras may provide reproducible assessments of left ventricular function with reduced radiation exposure...
April 2017: Current Cardiology Reports
keyword
keyword
50
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"